November 30, 2016 - By Winifred Garcia
Arrowhead (NASDAQ:ARWR) was lowered by Cantor Fitzgerald from a Buy rating to a Hold rating in a analysts note made public on Wednesday morning.
Out of 3 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $20.0 is the highest target while $8 is the lowest. The $14.33 average target is 733.14% above today’s ($1.72) stock price. Arrowhead Research Corp has been the topic of 5 analyst reports since August 5, 2015 according to StockzIntelligence Inc. On Wednesday, August 5 the stock rating was maintained by RBC Capital Markets with “Hold”. Cantor Fitzgerald initiated Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) rating on Friday, August 19. Cantor Fitzgerald has “Buy” rating and $15 price target. As per Thursday, May 19, the company rating was initiated by Chardan Capital Markets. The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) earned “Overweight” rating by Piper Jaffray on Friday, September 25. The firm has “Buy” rating given on Thursday, November 10 by Chardan Capital Markets.
About 268,696 shares traded hands. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has declined 26.09% since April 27, 2016 and is downtrending. It has underperformed by 31.32% the S&P500.
Analysts await Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to report earnings on December, 12. They expect $-0.33 EPS, up 21.43% or $0.09 from last year’s $-0.42 per share. After $-0.32 actual EPS reported by Arrowhead Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 3.13% negative EPS growth.
Insitutional Activity: The institutional sentiment is 0 in Q2 2016. Its the same as in 2016Q1. The ratio is without change, as 67 funds sold all Arrowhead Pharmaceuticals Inc shares owned while 0 reduced positions. only 0 funds bought stakes while 0 increased positions. They now own 6,170 shares or 99.97% less from 18.16 million shares in 2016Q1.
Hanson & Doremus Management, a Vermont-based fund reported 470 shares. Great West Life Assurance Can, a Manitoba – Canada-based fund reported 5,700 shares.
Insider Transactions: Since August 22, 2016, the stock had 0 insider buys, and 1 insider sale for $160,000 net activity. The insider Myszkowski Kenneth Allen sold 20,000 shares worth $160,000.
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, is a biopharmaceutical company. The company has a market cap of $262.51 million. The Firm is engaged in developing RiboNucleic Acid interference therapeutics. It currently has negative earnings. The Company’s products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA.
According to Zacks Investment Research, “Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.”
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, incorporated on February 13, 2001, is a biopharmaceutical company. The Firm is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi therapeutics leverage this natural pathway of gene silencing to target and shut down specific disease causing genes. The Company’s products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. The Company’s ARC-520 is an RNAi therapeutic designed to treat chronic hepatitis B virus (HBV) infection by reducing the expression and release of new viral particles and viral proteins with the goal of achieving a functional cure for HBV. The Firm is conducting multiple Phase IIb clinical efficacy studies. The Company’s ARC-AAT is an unlocked nucleobase analog (UNA), which contains RNAi therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), a rare genetic disease that can damage the liver and lungs of affected individuals. The Firm is conducting a Phase Ib clinical trial for ARC-AAT. The study is a multi-center, randomized, placebo-controlled, double blind, single dose-escalation, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of ARC-AAT and the effect on circulating AAT levels.
More notable recent Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) news were published by: Fool.com which released: “Why Arrowhead Pharmaceuticals Inc. Is Plummeting Today” on November 09, 2016, also Fool.com with their article: “What’s Next for Arrowhead Pharmaceuticals, Inc. After the Stock Meltdown?” published on November 10, 2016, Businesswire.com published: “Arrowhead Pharmaceuticals Announces Closing of License and Collaboration …” on November 21, 2016. More interesting news about Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) were released by: Prnewswire.com and their article: “ARWR LOSS ALERT: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc …” published on November 22, 2016 as well as Businesswire.com‘s news article titled: “Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders …” with publication date: November 23, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.